Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ARS Pharmaceuticals (SPRY) Revenue (2022 - 2025)

ARS Pharmaceuticals (SPRY) has disclosed Revenue for 4 consecutive years, with $28.1 million as the latest value for Q4 2025.

  • Quarterly Revenue fell 67.56% to $28.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $84.3 million through Dec 2025, down 5.46% year-over-year, with the annual reading at $84.3 million for FY2025, 5.46% down from the prior year.
  • Revenue hit $28.1 million in Q4 2025 for ARS Pharmaceuticals, down from $32.5 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $86.6 million in Q4 2024 to a low of $10000.0 in Q2 2023.
  • Historically, Revenue has averaged $14.6 million across 4 years, with a median of $1.4 million in 2022.
  • Biggest five-year swings in Revenue: crashed 97.84% in 2023 and later soared 4900.0% in 2024.
  • Year by year, Revenue stood at $189000.0 in 2022, then tumbled by 94.71% to $10000.0 in 2023, then skyrocketed by 865710.0% to $86.6 million in 2024, then crashed by 67.56% to $28.1 million in 2025.
  • Business Quant data shows Revenue for SPRY at $28.1 million in Q4 2025, $32.5 million in Q3 2025, and $15.7 million in Q2 2025.